Tamar Grossman

VP, Global Head of RNA, Gene Therapy and Delivery at Johnson & Johnson Innovative Medicine

Speaker

Tamar R. Grossman is the Vice President and the Global Head of RNA, Gene Therapy, and Delivery at Janssen Pharmaceutical Companies of Johnson and Johnson. Tamar and her team are responsible for the delivery of RNA based development candidates, Gene therapy and ADCs across all therapeutic areas. In addition, her team is exploring how oligonucleotide therapeutics and drug conjugates can be selectively targeted to design best-in-class drug candidates.

Throughout her career Tamar gained broad expertise in research and development of all RNA therapeutics modalities including siRNA, ASO, mRNA and replicon/saRNA. Previously, she was a Senior Director and Head of Rare Diseases at Arcturus Therapeutics where she and her team developed RNA therapeutics across different RNA modalities to rare and common diseases. Prior to Arcturus, Tamar was the Director of Translational Medicine at Ionis Pharmaceuticals where she led various antisense oligonucleotide therapeutics programs from concept up to successful clinical development.

Tamar received her PhD in Biochemistry from Tel-Aviv University in Israel. Her research focused on characterization neurotransmitter transporters and bioinformatics. She completed her postdoctoral research training at the UCSD where she focused on developing animal models to human diseases to decipher disease mechanisms for rare and complex genetic diseases.